Evaluation of the Sleep-relieving Effect of Banana Peel Extract

July 28, 2025 updated by: TCI Co., Ltd.

Explore Whether Banana Peel Extract Can Improve Sleep

Banana peel has the potential to improve sleep quality. The purpose of this research is to test the effect of banana peel on improving sleep quality.

Study Overview

Detailed Description

Insomnia is one of the most frequently complained sleep problems in sleep disorders, and in recent years has been regarded by the medical community as a disease that seriously affects people's lives and quality of life. The problem of perishable and perishable causes a great burden on the environment. However, banana peels actually contain many functional ingredients, such as dietary fiber, minerals, alkaloids, flavonoids, phenols, saponins, tannins and dopamine, etc. Banana peel contains more total phenols and total flavonoids than banana pulp. Studies have pointed out that banana peel extraction can inhibit the growth of fungi and bacteria. In addition, it also has antioxidant, anti-depressant, and diuretic functions. Banana peel can also improve the performance of tryptophan metabolism-related genes

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan
        • Taipei Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

1.20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent.

2.Pittsburgh Sleep Quality Index (PSQI) score> 5

Exclusion Criteria:

  1. Taking sleeping pills and melatonin
  2. People suffering from mental illness
  3. Pregnant or breastfeeding women
  4. People who are known to be allergic to bananas
  5. Have heart-related diseases
  6. People with symptoms of sleep cessation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
Experimental: Banana peel extract
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
Other Names:
  • Happy Banana

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep monitoring
Time Frame: at 4 week after taking test sample
Detect the electrical activity of the heart in the potential difference between two specific points on the body surface to reflect the state of sleep
at 4 week after taking test sample
Serotonin
Time Frame: at 4 week after taking test sample
Venous blood was sampled to measure concentrations of Serotonin
at 4 week after taking test sample
Melatonin
Time Frame: at 4 week after taking test sample
Collect saliva samples in the morning upon waking to measure melatonin concentration.
at 4 week after taking test sample
Sleeping quality
Time Frame: at 4 week after taking test sample
The Pittsburgh Sleep Quality Index (PSQI) will be utilized to assess sleeping quality. The minimum value is 0, the maximum value is 42. The higher the score, the worse the outcome.
at 4 week after taking test sample
Insomnia Severity
Time Frame: at 4 week after taking test sample
The Insomnia Severity Index (ISI) will be utilized to assess insomnia severity. The minimum value is 0, the maximum value is 28. The higher the score, the worse the outcome.
at 4 week after taking test sample

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change of liver function biomarkers (AST, ALT) of blood
Time Frame: at 4 week after taking test sample
Fasting venous blood was sampled to measure liver function biomarkers
at 4 week after taking test sample
The change of renal function biomarkers (creatinine, BUN) of blood
Time Frame: at 4 week after taking test sample
Fasting venous blood was sampled to measure renal function biomarkers
at 4 week after taking test sample
The change of fasting blood glucose
Time Frame: at 4 week after taking test sample
Fasting venous blood was sampled to measure concentrations of blood glucose
at 4 week after taking test sample
The change of Blood lipids profiles (Total-Cholesterol, HDL-C, LDL-C, triglycerides)
Time Frame: at 4 week after taking test sample
Fasting venous blood was sampled to measure concentrations of Blood lipids profiles (Total-Cholesterol, HDL-C, LDL-C, triglycerides)
at 4 week after taking test sample

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hsin-Chien Lee, Doctor, Taipei Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Actual)

May 31, 2024

Study Completion (Actual)

May 31, 2025

Study Registration Dates

First Submitted

October 21, 2021

First Submitted That Met QC Criteria

November 11, 2021

First Posted (Actual)

November 23, 2021

Study Record Updates

Last Update Posted (Actual)

July 30, 2025

Last Update Submitted That Met QC Criteria

July 28, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • N202103033

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Impaired Attention

Clinical Trials on Placebo

Subscribe